Monitoring of Mobility of Parkinson’s Patients for Therapeutic Purposes – Clinical Trial

Overview

When Parkinson Disease is mild, it responds well to treatment with drugs (L-Dopa and dopamine antagonists). However, as the disease progresses, the effect of the drugs diminishes and lasts for a shorter time (wearing-off), which require physicians to progressively increase and/or break up the dosage of dopamine drugs, to control symptoms over the course of the entire day. Despite this, most patients present motor fluctuations after 10 years. These fluctuations consist of changes between what are known as Off periods, when the medication does not produce an effect and mobility is hindered, and On periods when patients can move smoothly, with the medication producing its best effect. The timeline of these motor fluctuations over the course of the day and also on different days is very valuable to precisely adjust the medication. Nevertheless, neurologists do not currently have detailed information on the timeline of the symptoms of their patients, which means that they have serious difficulties to obtain good results with the adjustment of medication. Currently, the neurologist's information on the time progression of the motor fluctuations is drawn from what the patient indicates in the office visit, or in the best case, from diaries that the patient fills out at home, periodically (e.g. every hour) noting the motor state (On or Off). Although the latter method is still the gold standard in research and in care, it has serious limitations, because patients often forget to record the information (especially when they are in Off), many do not recognize their motor states well, and few can maintain adherence to such a laborious system for more than a few days. The Parkinson Holter (STAT-ON ®) is a wearable device, which objectively measures and records the motor fluctuations of the patients. It does not require intervention by the patient, and can, therefore, be used in daily life, long term if necessary. However, the concept that detailed knowledge of motor fluctuations of patients will lead to better control of the disease, thanks to optimisation of the therapeutic regimen, is still a hypothesis. To demonstrate or refute this hypothesis, we are now conducting a clinical trial, with this medical device, to study the clinical effectiveness in patients with moderate Parkinson's disease and motor fluctuations. This trial will show whether using the Parkinson Holter is better than the clinical interview used in traditional clinical practice (primary objective), and whether it is not inferior to the On-Off diary recorded by the patients at home (exploratory objective)

Full Title of Study: “Monitoring of Mobility of Parkinson’s Patients for Therapeutic Purposes – Clinical Trial”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Diagnostic
    • Masking: Triple (Participant, Investigator, Outcomes Assessor)
  • Study Primary Completion Date: September 30, 2022

Interventions

  • Device: Parkinson Holter
    • The neurologists will receive the wearable report (for medication adjustment, if any as per physician’s criteria/judgement)
  • Diagnostic Test: Motor fluctuations diary
    • The neurologists will receive the patient’s diary report (for medication adjustment, if any as per physician’s criteria/judgement).
  • Other: Traditional clinical practice
    • The neurologists will receive the patient & caregiver report at the time of the visit (for medication adjustment, if any as per physician’s criteria/judgement).

Arms, Groups and Cohorts

  • Active Comparator: Parkinson Holter
    • The neurologists in the study will receive information from the Parkinson Holter (device being studied)
  • Active Comparator: Parkinson’s diary
    • The neurologists in the study will receive information from a motor fluctuations diary
  • Placebo Comparator: Traditional clinical practice
    • The neurologists in the study will receive no additional information other than what is obtained during the visit

Clinical Trial Outcome Measures

Primary Measures

  • Daily time in Off
    • Time Frame: 7 days
    • Changes from baseline to last visit in daily hours in Off

Secondary Measures

  • Number of clinical contacts
    • Time Frame: 6 months
    • Number of patient visits and telephone controls to adjust medication
  • Patient’s adherence to the MF measurement system
    • Time Frame: 7 days
    • Total hour/days with information registered.
  • Number of therapeutic changes.
    • Time Frame: 6 months
    • Number of therapeutic changes done to improve symptoms.
  • Motor complications
    • Time Frame: 6 months
    • Changes from baseline to last visit in motor complications, assessed by means of Unified Parkinson’s Disease Rating Scale – part IV
  • Daily time in On
    • Time Frame: 7 days
    • Changes from baseline to last visit in daily hours in On
  • Change of presence and severity of freezing of gait episodes
    • Time Frame: 7 days
    • Changes from baseline to last visit in the number and severity of freezing of gait episodes, assessed by means of Freezing of Gait Questionnaire
  • Reported quality of life
    • Time Frame: 1 month
    • Changes from baseline to last visit in quality of life, assessed by menas of Parkinson’s Disease Questionnaire-39
  • Activities of Daily Living
    • Time Frame: 6 months
    • Changes from baseline to last visit in dependence for Activities of Daily Living assessed by means of Unified Parkinson’s Disease Rating Scale – part II
  • User satisfaction: Quebec User Evaluation of Satisfaction with assistive Technology
    • Time Frame: 7 days
    • Physician and patient satisfaction with the Parkinson Holter will be assessed by means of the Quebec User Evaluation of Satisfaction with assistive Technology (QUEST)
  • System usability: System Usability Scale
    • Time Frame: 7 days
    • Usability of the system will be assessed by System Usability Scale (SUS)

Participating in This Clinical Trial

Inclusion Criteria

  • Ideopathic Parkinson's Disease – Disease in the moderate-severe phase (Hoehn & Yahr ≥ 2 en Off) – Motor fluctuations (with at least 2h/day in Off) – Agree to participate voluntarily and will sign a written consent form Exclusion Criteria:

  • Incapable of walking independently or H&Y=5 – Participating in another clinical trial – Patients with acute intercurrent disease – Psychiatric or cognitive disorders that prevent collaboration (MMSE <24)

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Consorci Sanitari de l’Alt Penedès i Garraf
  • Collaborator
    • Instituto de Salud Carlos III
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Alejandro Rodríguez-Molinero, PhD/MD, Study Director, Consorci Sanitari de l’Alt Penedès i Garraf
  • Overall Contact(s)
    • Alejandro Rodríguez-Molinero, PhD/MD, 34-938940025, arodriguez@csapg.cat

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.